Inhaled Dry Powder of Antiviral Agents: A Promising Approach to Treating Respiratory Viral Pathogens
Inhaled dry powder formulations of antiviral agents represent a novel and potentially transformative approach to managing respiratory viral infections. Traditional antiviral therapies in the form of tablets or capsules often face limitations in terms of therapeutic activity, systemic side effects, a...
Saved in:
| Main Authors: | , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
MDPI AG
2025-02-01
|
| Series: | Viruses |
| Subjects: | |
| Online Access: | https://www.mdpi.com/1999-4915/17/2/252 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1850077951250399232 |
|---|---|
| author | Tushar Saha Zia Uddin Masum Anik Biswas Moushumi Afroza Mou Sohag Ahmed Tamal Saha |
| author_facet | Tushar Saha Zia Uddin Masum Anik Biswas Moushumi Afroza Mou Sohag Ahmed Tamal Saha |
| author_sort | Tushar Saha |
| collection | DOAJ |
| description | Inhaled dry powder formulations of antiviral agents represent a novel and potentially transformative approach to managing respiratory viral infections. Traditional antiviral therapies in the form of tablets or capsules often face limitations in terms of therapeutic activity, systemic side effects, and delayed onset of action. Dry powder inhalers (DPIs) provide a targeted delivery system, ensuring the direct administration of antivirals to the infection site, the respiratory tract, which potentially enhance therapeutic efficacy and minimize systemic exposure. This review explores the current state of inhaled dry powder antiviral agents, their advantages over traditional routes, and specific formulations under development. We discuss the benefits of targeted delivery, such as improved drug deposition in the lungs and reduced side effects, alongside considerations related to the formulation preparation. In addition, we summarize the developed (published and marketed) inhaled dry powders of antiviral agents. |
| format | Article |
| id | doaj-art-3bf27ce60f6e48cfa0c1e95c41cabb64 |
| institution | DOAJ |
| issn | 1999-4915 |
| language | English |
| publishDate | 2025-02-01 |
| publisher | MDPI AG |
| record_format | Article |
| series | Viruses |
| spelling | doaj-art-3bf27ce60f6e48cfa0c1e95c41cabb642025-08-20T02:45:42ZengMDPI AGViruses1999-49152025-02-0117225210.3390/v17020252Inhaled Dry Powder of Antiviral Agents: A Promising Approach to Treating Respiratory Viral PathogensTushar Saha0Zia Uddin Masum1Anik Biswas2Moushumi Afroza Mou3Sohag Ahmed4Tamal Saha5Mastaplex Ltd., Centre for Innovation, University of Otago, Dunedin 9016, New ZealandCollege of Pharmacy and Health Sciences, St. John’s University, Queens, New York, NY 11439, USAMaterials and Nanotechnology, North Dakota State University, Fargo, ND 58105, USADepartment of Biological Science, St. John’s University, Queens, New York, NY 11439, USADepartment of Chemistry, West Virginia University, Morgantown, WV 26506, USAInternational Centre for Diarrheal Disease Research, Bangladesh, Dhaka 1212, BangladeshInhaled dry powder formulations of antiviral agents represent a novel and potentially transformative approach to managing respiratory viral infections. Traditional antiviral therapies in the form of tablets or capsules often face limitations in terms of therapeutic activity, systemic side effects, and delayed onset of action. Dry powder inhalers (DPIs) provide a targeted delivery system, ensuring the direct administration of antivirals to the infection site, the respiratory tract, which potentially enhance therapeutic efficacy and minimize systemic exposure. This review explores the current state of inhaled dry powder antiviral agents, their advantages over traditional routes, and specific formulations under development. We discuss the benefits of targeted delivery, such as improved drug deposition in the lungs and reduced side effects, alongside considerations related to the formulation preparation. In addition, we summarize the developed (published and marketed) inhaled dry powders of antiviral agents.https://www.mdpi.com/1999-4915/17/2/252dry powderantiviralrespiratorypathogensinfections |
| spellingShingle | Tushar Saha Zia Uddin Masum Anik Biswas Moushumi Afroza Mou Sohag Ahmed Tamal Saha Inhaled Dry Powder of Antiviral Agents: A Promising Approach to Treating Respiratory Viral Pathogens Viruses dry powder antiviral respiratory pathogens infections |
| title | Inhaled Dry Powder of Antiviral Agents: A Promising Approach to Treating Respiratory Viral Pathogens |
| title_full | Inhaled Dry Powder of Antiviral Agents: A Promising Approach to Treating Respiratory Viral Pathogens |
| title_fullStr | Inhaled Dry Powder of Antiviral Agents: A Promising Approach to Treating Respiratory Viral Pathogens |
| title_full_unstemmed | Inhaled Dry Powder of Antiviral Agents: A Promising Approach to Treating Respiratory Viral Pathogens |
| title_short | Inhaled Dry Powder of Antiviral Agents: A Promising Approach to Treating Respiratory Viral Pathogens |
| title_sort | inhaled dry powder of antiviral agents a promising approach to treating respiratory viral pathogens |
| topic | dry powder antiviral respiratory pathogens infections |
| url | https://www.mdpi.com/1999-4915/17/2/252 |
| work_keys_str_mv | AT tusharsaha inhaleddrypowderofantiviralagentsapromisingapproachtotreatingrespiratoryviralpathogens AT ziauddinmasum inhaleddrypowderofantiviralagentsapromisingapproachtotreatingrespiratoryviralpathogens AT anikbiswas inhaleddrypowderofantiviralagentsapromisingapproachtotreatingrespiratoryviralpathogens AT moushumiafrozamou inhaleddrypowderofantiviralagentsapromisingapproachtotreatingrespiratoryviralpathogens AT sohagahmed inhaleddrypowderofantiviralagentsapromisingapproachtotreatingrespiratoryviralpathogens AT tamalsaha inhaleddrypowderofantiviralagentsapromisingapproachtotreatingrespiratoryviralpathogens |